Antares Pharma, Inc. (ATRS) Given “Buy” Rating at HC Wainwright
HC Wainwright reissued their buy rating on shares of Antares Pharma, Inc. (NASDAQ:ATRS) in a research report report published on Wednesday morning. The brokerage currently has a $3.50 target price on the specialty pharmaceutical company’s stock.
ATRS has been the subject of several other research reports. Piper Jaffray Companies reaffirmed a buy rating on shares of Antares Pharma in a research note on Friday, September 8th. Vetr raised shares of Antares Pharma from a buy rating to a strong-buy rating and set a $3.42 target price for the company in a research note on Monday, July 24th. Finally, ValuEngine downgraded shares of Antares Pharma from a hold rating to a sell rating in a research note on Monday, October 16th. One investment analyst has rated the stock with a sell rating, three have issued a buy rating and two have assigned a strong buy rating to the company’s stock. The stock presently has a consensus rating of Buy and a consensus price target of $3.84.
Shares of Antares Pharma (ATRS) opened at $1.84 on Wednesday. Antares Pharma has a 12 month low of $1.58 and a 12 month high of $4.09. The company has a quick ratio of 3.04, a current ratio of 3.34 and a debt-to-equity ratio of 0.69.
Antares Pharma (NASDAQ:ATRS) last issued its earnings results on Tuesday, November 7th. The specialty pharmaceutical company reported ($0.03) EPS for the quarter, meeting the Thomson Reuters’ consensus estimate of ($0.03). Antares Pharma had a negative net margin of 32.06% and a negative return on equity of 43.05%. The firm had revenue of $15.10 million during the quarter, compared to the consensus estimate of $14.01 million. The business’s revenue was up 11.9% compared to the same quarter last year. equities analysts expect that Antares Pharma will post -0.11 EPS for the current fiscal year.
WARNING: “Antares Pharma, Inc. (ATRS) Given “Buy” Rating at HC Wainwright” was originally published by Watch List News and is the sole property of of Watch List News. If you are accessing this article on another website, it was illegally copied and republished in violation of US and international trademark and copyright legislation. The original version of this article can be read at https://www.watchlistnews.com/antares-pharma-inc-atrs-given-buy-rating-at-hc-wainwright/1697210.html.
In other news, Director Thomas J. Garrity sold 30,000 shares of the company’s stock in a transaction that occurred on Tuesday, October 3rd. The shares were sold at an average price of $3.50, for a total value of $105,000.00. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, Director Leonard S. Jacob sold 230,000 shares of the company’s stock in a transaction that occurred on Monday, October 9th. The shares were sold at an average price of $4.05, for a total transaction of $931,500.00. The disclosure for this sale can be found here. 11.60% of the stock is owned by corporate insiders.
Several institutional investors have recently added to or reduced their stakes in ATRS. Capital Advantage Inc. acquired a new position in shares of Antares Pharma in the third quarter valued at approximately $110,000. Alliancebernstein L.P. acquired a new position in shares of Antares Pharma in the second quarter valued at approximately $119,000. Legal & General Group Plc acquired a new position in shares of Antares Pharma in the second quarter valued at approximately $120,000. MML Investors Services LLC boosted its holdings in shares of Antares Pharma by 228.2% in the second quarter. MML Investors Services LLC now owns 43,147 shares of the specialty pharmaceutical company’s stock valued at $139,000 after buying an additional 30,000 shares during the period. Finally, Credit Suisse AG acquired a new position in shares of Antares Pharma in the first quarter valued at approximately $146,000. Institutional investors own 37.00% of the company’s stock.
Antares Pharma Company Profile
Antares Pharma, Inc (Antares) is a specialty pharmaceutical company that focuses on developing and commercializing self-administered parenteral pharmaceutical products and technologies. The Company develops and manufactures pressure-assisted injector devices, with and without needles, which allow patients to self-inject drugs.
Receive News & Ratings for Antares Pharma Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Antares Pharma Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.